C-MER Medical Signals Profit Turnaround on Network Optimisation, Absence of Impairment Charges

C-MER Eye Care Holdings Limited ( (HK:3309) ) has provided an update.

C-MER Medical Holdings Limited has issued a positive profit alert, indicating it expects to swing to a net profit of between HK$90 million and HK$110 million attributable to shareholders for the year ended 31 December 2025, compared with a HK$135.2 million loss a year earlier. The turnaround is driven by a modest rise in revenue to about HK$1.95 billion, strategic optimisation of its service network including closure of non-performing operations, and the absence of major impairment charges that had weighed on the 2024 results.

The announcement underscores a significant recovery in the group’s financial performance and suggests that its efficiency measures are beginning to deliver tangible benefits. Investors are advised that the figures are based on unaudited management accounts, with detailed annual results for 2025 expected by the end of March 2026, and are urged to exercise caution when dealing in the company’s shares ahead of the finalised numbers.

The most recent analyst rating on (HK:3309) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on C-MER Eye Care Holdings Limited stock, see the HK:3309 Stock Forecast page.

More about C-MER Eye Care Holdings Limited

C-MER Medical Holdings Limited is a Hong Kong-listed medical services group focused on ophthalmic and related healthcare services. Through its network of clinics and medical facilities, the company provides specialist eye care and broader medical treatments to patients across its service regions, with an emphasis on operational efficiency and network optimisation.

Average Trading Volume: 371,423

Technical Sentiment Signal: Sell

Current Market Cap: HK$1.69B

For an in-depth examination of 3309 stock, go to TipRanks’ Overview page.